We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
C4x Discovery Holdings Plc | LSE:C4XD | London | Ordinary Share | GB00BQQ2RV18 | ORD 1P |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
13.80 | 14.20 | 14.25 | 12.95 | 12.95 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 1.71M | -11.11M | -0.0441 | -3.13 | 34.81M |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
16:20:01 | O | 25,000 | 13.932 | GBX |
Date | Time | Source | Headline |
---|---|---|---|
23/1/2024 | 13:57 | UKREG | C4X Discovery Holdings PLC Result of AGM |
18/1/2024 | 07:00 | UKREG | C4X Discovery Holdings PLC Board Update |
04/1/2024 | 14:45 | UKREG | C4X Discovery Holdings PLC Holding(s) in Company |
03/1/2024 | 10:06 | ALNC | TAKING AIM: C4X's Astra deal shows value to investors - Shore Capital |
03/1/2024 | 09:25 | DJN | C4X Discovery Shares Rise on AstraZeneca Milestone Payment |
03/1/2024 | 08:04 | ALNC | C4X receives USD11 million from AstraZeneca following NRF2 trials |
03/1/2024 | 07:00 | UKREG | C4X Discovery Holdings PLC AstraZeneca $11m milestone payment to C4XD |
18/12/2023 | 15:31 | UKREG | C4X Discovery Holdings PLC Posting of 2023 Annual Report and Notice of AGM |
14/12/2023 | 11:25 | ALNC | C4X Discovery shares topple 10% as loss widens on higher costs |
14/12/2023 | 07:00 | UKREG | C4X Discovery Holdings PLC Full Year Results |
C4x Discovery (C4XD) Share Charts1 Year C4x Discovery Chart |
|
1 Month C4x Discovery Chart |
Intraday C4x Discovery Chart |
Date | Time | Title | Posts |
---|---|---|---|
18/3/2024 | 16:15 | C4X Discovery Holdings plc | 3,060 |
03/1/2024 | 08:46 | c4xd Astra Zeneca $11m Milestone payment | 3 |
Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
---|---|---|---|---|
2024-03-18 16:20:02 | 13.93 | 25,000 | 3,483.00 | O |
2024-03-18 16:19:25 | 13.93 | 25,000 | 3,483.00 | O |
2024-03-18 16:15:26 | 13.80 | 149 | 20.56 | AT |
2024-03-18 15:40:46 | 14.07 | 7,765 | 1,092.38 | O |
2024-03-18 15:32:24 | 14.25 | 1 | 0.14 | UT |
Top Posts |
---|
Posted at 18/3/2024 08:20 by C4x Discovery Daily Update C4x Discovery Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker C4XD. The last closing price for C4x Discovery was 13p.C4x Discovery currently has 252,227,097 shares in issue. The market capitalisation of C4x Discovery is £34,807,339. C4x Discovery has a price to earnings ratio (PE ratio) of -3.13. This morning C4XD shares opened at 12.95p |
Posted at 22/2/2024 17:28 by takeiteasy but if the result is some knowledgeable committed shareholders who are able to make a determination of the true value of a business like ours then it is a price worth paying in my book .... |
Posted at 24/1/2024 14:34 by luckyabbeygale Well the 1.5p has put my spreadbet into a £1,000 loss. As my average price is 14p.However it wouldnt matter if they took another 4p off the price. As my spreadbet account is made up of so many shares. That it would take a massive dow crash to wipe me out. |
Posted at 22/1/2024 21:07 by bloomberg2 ETX usually the poor relation!! To C4XD .... |
Posted at 20/1/2024 08:49 by takeiteasy An evolutionary yearHunjan said that C4XD is always in discussions with potential partners as they progress their programmes along the development pathway, and partnership is something that could eventually happen with its ongoing work on IBD and other inflammatory diseases. The company is also planning to publish results from its analysis, using PatientSeek, of two phase three clinical trials for Parkinson’s with the Garvan Institute of Medical Research. The sheer broad range of the work being considered is what makes this such a fascinating business to link up with if you have an interest in the world of auto-immunity dyor and no advice intended |
Posted at 06/1/2024 06:54 by takeiteasy UPDATE: Dr Julie Simmonds at Panmure Gordon commented: “C4XD has received an $11m milestone payment from AstraZeneca. We update our estimates. The payment, in addition to the divestment of the Orexin programme in July which generated £16m, means we expect the company to end the year (July) with Net Cash of £22m, the current market capitalization. C4XD is very good value with a strong drug development engine; there are few companies which have successfully developed and out-licensed three differentiated products. We reiterate our BUY recommendation.̶hxxps://www.thebusin hxxps://www.lgbco.co |
Posted at 05/1/2024 14:41 by mirabeau DM - todayIt’s fair to say C4X Discovery had a fantastic start with the shares advancing 113 per cent over the foreshortened trading week after drug giant AstraZeneca delivered an $11million post-Christmas windfall. It came in the form of what the experts call a ‘milestone payment’ under a $402million deal with Anglo-Swedish giant, which has licensed the right to NRF2 activator, created by C4XD to tackle chronic respiratory disease. Analysts said the payment went further than adding a material sum to the AIM company’s coffers – it provided third-party validation of the technology. 'We see this as an important value inflexion which should reinvigorate sentiment in the share,' said regional broker Shore Capital. 'Moreover, this serves as a timely reminder that C4XD has licensing deals in place with some of the leading developers for its programmes.' |
Posted at 03/1/2024 11:39 by intoodeep News of C4X Discovery Holdings PLC (AIM:C4XD)’s latest payment from AstraZeneca PLC (LSE:AZN) solidifies and validates the company’s place as a skilled drug developer, analysts have said.Following the firm’s update that US$11 million had been received under a deal worth up to US$400 million with AstraZeneca for the NRF2 activator programme, Shore Cap analysts backed aim-listed C4X. “We see this as an important value inflection which should reinvigorate sentiment in the share,” the bank said in a note. “Moreover, this serves as a timely reminder that C4XD has licensing deals in place with some of the leading developers for its programmes.” The deal included an initial upfront payment of US$2 million to C4X and consisted of a series of developmental and commercial milestones. Under this, C4X’s NRF2 activator programme has been out-licensed to AstraZeneca with the goal of creating an oral therapy for inflammatory and respiratory diseases. Shore Cap added that its model for C4X suggested fair value of 52p per share, marking a prospective 480% increase on Tuesday’s closing value of 8.7p. “These agreements serve as strong validation of C4XD’s prowess in drug discovery and demonstrate its ability to distil value from assets early in the development process,” the bank said. Indeed, the market reacted positively to the news, with shares in C4X climbing 37% to 11.98p following the news on Wednesday morning. |
Posted at 14/12/2023 06:50 by bloomberg2 Morning all!!! Results in 10 minutes hopefully forward looking statement will stop the fall in share price |
Posted at 09/12/2023 17:25 by golden prospect Something very interesting in play, on radar.From AR2022 "During November 2020 £15.0 million (before expenses) was raised via a placing of 99,169,286 ordinary shares and an open offer for 7,973,572 ordinary shares at 14 pence each. In addition, 99,169,286 warrants were issued over ordinary shares, exercisable at 28p per share with an exercise period of 5 years." Clearly an easy short from 2022 @ 45p Stock is tight, Richard Griffiths 22.07%, Polar Capital 17.84%, Lombard Odier 17.29 (have been increasing), Baillie Gifford 8.52%, Canaccord Genuity Wealth Mgt 4.54%, Calculus Capital 3.63%, Herald Investment Mgt 2.67 76.56% accounted for, guess small float leads to distorted share price. Someone ready/building to make an offer ? |
Posted at 07/12/2023 13:43 by smithless Is this a buy? Share price has totally collapsed recently. Looks OK for cash. Is there something wrong with the science? |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
ADVFN France ADVFN US ADVFN Korea |